Valeo Pharma says awarded multi-year listing agreements by two of Canada’s largest Group Purchasing Organizations for Redesca

Valeo Pharma Inc said it has been awarded multi-year listing agreements by two of Canada’s largest Group Purchasing Organizations (GPO) for its anticoagulant drug Redesca as well as three additional hospital specialty products.

Under the terms of the contracts, the GPOs have listed Redesca and Redesca HP, Valeo Pharma’s leading low molecular weight heparin (LMWH) biosimilar, as well as Amikacin, Ethacrynate Sodium and Benztropine, for three years starting on October 1, 2021.

“These listing agreements significantly expand the number of Canadian hospitals that can now access Redesca. Increased hospital accessibility, coupled with extensive public and private reimbursement coverage, provides a solid foundation to support the continued growth of Redesca,” Valeo Pharma CEO Steve Saviuk said in a statement. “The Canadian hospital market is highly sought-after and competitive, our commercial team continues to deliver results in this environment.”

READ: Valeo Pharma reaches milestone as it completes negotiations with pan-Canadian Pharmaceutical Alliance for Enerzair and Atectura

The company said its new corporate structure and commercial platform allows it to successfully pursue and develop strong partnerships with leading GPOs across the country and better service their evolving needs. 

“The support provided by our dedicated team of key account managers and medical affairs professionals combined with the strong supply chain in place make Redesca’s value proposition very attractive for hospitals,” Valeo Pharma president and chief operating officer Frederic Fasano added.  

Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on respirology, neurodegenerative diseases, oncology and other specialty products. 

Headquartered in Kirkland, Quebec, the company has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. 

Contact the author at [email protected]

Story by ProactiveInvestors